Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs . Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults .
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.
• Treatment of symptomatic gastroesophageal reflux disease (GERD) in
patients 1 year of age and older
• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in
patients 1 month of age and older
• Maintenance of healing of EE due to acid-mediated GERD in patients 1
year of age and older
• Pathologic hypersecretory conditions in adults
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2015-01-01
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT02299687
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers
- Conditions
- Interventions
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Dexa Medica Group
- Target Recruit Count
- 32
- Registration Number
- NCT02262169
- Locations
- 🇮🇩
Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Udayana Sanglah General Hospital, Denpasar, Bali, Indonesia
Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02256813
The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02254148
- Locations
- 🇩🇪
1307.19.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT02253875
Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 54
- Registration Number
- NCT02249871
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 18
- Registration Number
- NCT02249936
- Locations
- 🇺🇸
ICON Development Solutions, Omaha, Nebraska, United States
Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-09-18
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 34
- Registration Number
- NCT02243553
A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 18
- Registration Number
- NCT02229877
A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 72
- Registration Number
- NCT02220777
- Locations
- 🇧🇪
SGS Belgium N.V., Antwerp, Belgium
🇫🇷SGS Aster, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.